Alvotech announces expected global market entry dates for avt04 biosimilar to stelara® (ustekinumab)

Reykjavik, iceland, feb. 15, 2024 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement agreements with johnson & johnson in japan, canada and in the european economic area (eea) for avt04, a biosimilar to stelara® (ustekinumab). regulatory approval for avt04 in these markets has already been granted. market applications for avt04 are currently pending in additional global markets, including in the u.s.
ALVO Ratings Summary
ALVO Quant Ranking